tada, and to add to that (assuming I understood it exactly), Don stated that at the BOM trial, we saw a 67% relative risk reduction in the patient group representing diabetics, chronic kidney disease patients and those on sglt2. In BOM2, we're really looking for a 22% relative risk reduction.
Koo